Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EBAC European Biotech Acquisition Corp
- Stocks
- Financial Services
- NASDAQ: EBAC
Price (delayed)
$11.19
Market cap
$183.5M
P/E Ratio
559.5
Dividend/share
N/A
EPS
$0.02
Enterprise value
$183.19M
Highlights
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
Key stats
What are the main financial stats of EBAC
Market
Valuations
Earnings
Shares outstanding
16.4M
Market cap
$183.5M
Enterprise value
$183.19M
Price to earnings (P/E)
559.5
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$2.82M
Net income
$342,895
EBIT
$342,895
EBITDA
$342,895
Free cash flow
-$514,792
Per share
Balance sheet
Liquidity
EPS
$0.02
EPS diluted
$0.02
Free cash flow per share
-$0.03
Book value per share
-$0.49
Revenue per share
$0
TBVPS
$7.91
Total assets
$129.75M
Total liabilities
$8.55M
Debt
$0
Equity
-$8.06M
Working capital
-$438,931
Debt to equity
0
Current ratio
0.45
Quick ratio
0.39
Net debt/EBITDA
-0.9
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
0.3%
Return on equity
N/A
Return on invested capital
0.3%
Return on capital employed
0.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBAC stock price
How has the European Biotech Acquisition stock price performed over time
Intraday
-4.44%
1 week
13.6%
1 month
10.14%
1 year
15.01%
YTD
10.79%
QTD
10.79%
Financial performance
How have European Biotech Acquisition's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$2.82M
Net income
$342,895
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 156% YoY and by 29% from the previous quarter
European Biotech Acquisition's net income has shrunk by 77% YoY and by 60% QoQ
Price vs fundamentals
How does EBAC's price correlate with its fundamentals
Growth
What is European Biotech Acquisition's growth rate over time
Valuation
What is European Biotech Acquisition stock price valuation
P/E
559.5
P/B
N/A
P/S
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year
Efficiency
How efficient is European Biotech Acquisition business performance
The ROA has plunged by 75% YoY and by 57% from the previous quarter
The return on invested capital has dropped by 75% year-on-year and by 57% since the previous quarter
Dividends
What is EBAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBAC.
Financial health
How did European Biotech Acquisition financials performed over time
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
The company's current ratio has shrunk by 75% YoY but it has surged by 61% QoQ
EBAC's debt is 100% more than its equity
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.